Podcasts about drugmaker

Blockbuster drugs. Rising profits. Strong sales. And yet, Novo Nordisk, the Danish company behind the GLP-1 drugs Ozempic and Wegovy, made a surprising move last week: It pushed out its CEO. WSJ's Peter Loftus charts the rise of Ozempic and the fall of CEO Lars Jorgensen. Jessica Mendoza hosts.  Further Listening: Trillion Dollar Shot  Why WeightWatchers Wants in on Drugs Like Ozempic   Sign up for WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Welcome to the Daily Compliance News. Each day, Tom Fox, the Voice of Compliance, brings you compliance-related stories to start your day. Sit back, enjoy a cup of morning coffee, and listen in to the Daily Compliance News—all from the Compliance Podcast Network. Each day, we consider four stories from the business world: compliance, ethics, risk management, leadership, or general interest for the compliance professional. Top stories include: Drugmaker to buy genetic data company. (WSJ) Defense boom corruption hits NATO. (dw.com) Disparate impact change tees up compliance risk. (Bloomberg Law) State AGs fill the AI regulatory role.  (Reuters) Learn more about your ad choices. Visit megaphone.fm/adchoices

Maria Lloyd, VP at Harrow, explains the pharma company's newly launched DTC program, meant to help patients access its dry-eye treatment at a reduced cash price, as well as patient-centric models as a blueprint for others, in conversation with MM+M's Lecia Bushak.And for our Trends segment, we discuss the spate of editorials written by mainstream and medical media in response to the Trump administration's vaccine policy.Music by Sixième Son Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.

Stephen Grootes speaks to Sean Capazorio, CFO at Aspen Pharmaceuticals about the Pharmacare's positive interim financial results. The Money Show is a podcast hosted by well-known journalist and radio presenter, Stephen Grootes. He explores the latest economic trends, business developments, investment opportunities, and personal finance strategies. Each episode features engaging conversations with top newsmakers, industry experts, financial advisors, entrepreneurs, and politicians, offering you thought-provoking insights to navigate the ever-changing financial landscape. The Money Show is a podcast hosted by well-known journalist and radio presenter, Stephen Grootes. He explores the latest economic trends, business developments, investment opportunities, and personal finance strategies. Each episode features engaging conversations with top newsmakers, industry experts, financial advisors, entrepreneurs, and politicians, offering you thought-provoking insights to navigate the ever-changing financial landscape. Thank you for listening to The Money Show podcast. Listen live - The Money Show with Stephen Grootes is broadcast weekdays between 18:00 and 20:00 (SA Time) on 702 and CapeTalk. There’s more from the Money Show on Primediaplus.com Subscribe to the Money Show daily and weekly newsletters The Money Show is brought to you by Absa. Follow us here 702 on Facebook: www.facebook.com/TalkRadio702 702 on TikTok: www.tiktok.com/@talkradio 702 on Instagram: www.instagram.com/talkradio702 702 on X: www.x.com/Radio702 702 on YouTube: www.youtube.com/@radio702 CapeTalk on Facebook: www.facebook.com/CapeTalk CapeTalk on TikTok: www.tiktok.com/@capetalk CapeTalk on Instagram: www.instagram.com/capetalkza CapeTalk on YouTube: www.youtube.com/@CapeTalk567 CapeTalk on X: www.x.com/CapeTalk See omnystudio.com/listener for privacy information.

The 340B drug pricing program is designed to give hospitals the flexibility to use their savings toward the types of patient care and support that their communities need the most. How does that work for hospitals that decide to use their access to 340B to provide the discounts directly to patients who cannot afford their drugs? Paul Orth, 340B program manager at University Health Kansas City Truman Medical Center, sits down with us to discuss how his health system's direct drug savings program is helping both uninsured and underinsured patients.How the program worksOrth says his system's direct savings program is built into the system that prescribes medication electronically from its clinics and its hospitals' electronic medical records system. When the prescriptions that generate from those visits are sent to a system pharmacy, 340B eligibility codes are attached that allows the pharmacy to know that they are eligible to receive the drugs at the 340B-discounted price plus a dispensing fee.Underinsured patients also benefitOrth says University Health describes its direct savings model as an uninsured program because that describes the key patient population that benefits from receiving the 340B price. But that assistance also is available for underinsured patients who otherwise would be expected to pay more in prescription drug copays than the 340B price. Drugmaker restrictions are a barrierOrth says this program is the difference between patients receiving a needed medication and going without one, which prevents hospital readmissions and emergency department visits. But he also notes that drug company restrictions limiting 340B pricing to a single contract pharmacy are negatively affecting the program, ultimately adding another barrier for access to care. Resources:340B Health Urges HRSA To Block J&J Plan To Replace 340B Discounts With RebatesJ&J Implements 340B Rebate Model Despite HRSA Opposition340B Health Equity Report 2023

Stephen Grootes speaks to Stephen Saad, Founder and CEO of Aspen, about the company's year-end results, highlighting key successes, challenges, and future prospects in the pharmaceutical industry.See omnystudio.com/listener for privacy information.

In an intriguing development in the pharmaceutical world, the maker of the popular weight loss drug Ozempic has announced plans to investigate how their medication might impact alcohol consumption. Ozempic, originally approved for the treatment of Type 2 diabetes, has gained significant attention for its effectiveness in promoting weight loss, sparking interest not just among those it was intended for but also in the wider community looking for effective weight management solutions.Ozempic works by mimicking a hormone called glucagon-like peptide-1 (GLP-1) that targets areas of the brain involved in appetite regulation. By doing so, it slows down stomach emptying, helps control blood sugar levels, and reduces appetite, which collectively contribute to weight loss. Patients using Ozempic have reported substantial weight loss, with many experiencing more than the average outcomes seen in clinical trials, especially when combined with lifestyle modifications such as diet and exercise.The exploration into how Ozempic affects alcohol consumption stems from observations and anecdotal reports that suggest a possible interaction between GLP-1 agonists, the class of drugs to which Ozempic belongs, and reduced craving or consumption of alcohol. This potential effect could have significant implications, not only for weight management but also for conditions related to excessive alcohol consumption such as liver disease, cardiovascular health, and addiction.Research into the interaction between GLP-1 agonists and alcohol consumption is still in the early stages, but initial studies suggest that these drugs may modulate the reward systems in the brain that are also involved in addiction behaviors, including alcohol use. If Ozempic can indeed influence these pathways, it might emerge as a multi-faceted therapy with both metabolic and psychiatric applications, offering a novel approach to managing alcohol dependence in conjunction with obesity and diabetes.The company's plan to conduct comprehensive studies on Ozempic's effects on alcohol consumption highlights a growing recognition of the complex interactions between metabolic, behavioral, and psychological health factors. These studies will likely involve both observational and controlled trial designs to ascertain the extent and nature of the interactions between Ozempic and alcohol. The findings could lead to new guidelines and recommendations for the use of GLP-1 agonists in clinical practice, potentially expanding the therapeutic scope of drugs like Ozempic.As obesity and alcohol misuse remain significant public health challenges worldwide, these insights could have profound health implications. They might not only lead to better management strategies for individuals struggling with weight and alcohol issues but could also enhance our understanding of the neurochemical pathways that underlie these behaviors.This upcoming research will be closely watched by both the medical community and the public, as it could usher in a new era of integrated therapy options that address multiple facets of health simultaneously. As we await the detailed study designs and outcomes, it is important to note that all uses of medications like Ozempic should be under the guidance of a healthcare provider, tailored to the specific needs and health conditions of each individual.

Today is Tuesday, January 16, and we're looking at Eli Lilly vs. Novo Nordisk.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

VLA1553, commercially known as Ixchiq, has received USFDA clearance and will be launched in India — which has seen high number of chikungunya cases — after ‘regulatory talks with DCGI'.----more----Read full article here: https://theprint.in/health/worlds-1st-vaccine-against-chikungunya-primed-for-launch-in-india-says-french-drugmaker-valneva/1846509/

Shares of Intel and GE both reaching milestones today, but how should you read into the rise of these old guard stocks? Plus, Novo Nordisk hitting all-time highs today as demand for its weight loss drugs continues to surge. Where's the name heading from here Fast Money Disclaimer 

After years of anticipation, California Gov. Gavin Newsom said the state would contract with Civica, a Utah-based generic pharmaceutical company, to start producing California-branded insulin, available for $30 for a 10 mL vial. Once the Food and Drug Administration approves the new insulin, Civica can begin manufacturing. Reporter Rachel Bluth talks with host Ben Leonard about about the deal.

In today's episode, Allie McCallion and Charity Blue, members of Morningstar Inc's sustainability team, discuss pay equity and three undervalued companies that are leading the charge. Timestamps00:00 Introduction00:27 Broadcom rides AI wave01:41 Costco shows resilience02:15 Eli Lilly cuts insulin costs03:55 Morningstar's internal sustainability team joins Investing Insights to discuss Equal Pay Day04:29 Where do women's earnings in the U.S. stand compared to men?05:30 What has research shown when companies practice pay equity?06:16 What did your team look for when they reviewed pay equity practices among big U.S. companies?07:06 3 Undervalued Stocks That Stress Equal Pay11:35 Should You Buy Stocks or a 4% CD?Read about topics from this episode.Broadcom Riding AI Wave to Robust Networking Sales in 2023; Raising FVE to $640 Per Sharehttps://www.morningstar.com/stocks/xnas/avgo/quoteCostco's Resilience Proves Its Ongoing Relevance and Brand Strength; Shares Fairly Valuedhttps://www.morningstar.com/stocks/xnas/cost/quoteEli Lilly's Insulin Price Cut Should Address Government's Critical Eye; but no Impact on FVEhttps://www.morningstar.com/stocks/xnys/lly/quote3 Stocks That Stress Equal Pay as We Observe International Women's Dayhttps://www.morningstar.com/articles/1141925/3-stocks-that-stress-equal-pay-as-we-observe-international-womens-dayRead what our team is writing:Allie McCallion https://www.morningstar.com/authors/2642/allie-mccallionCharity Blue https://www.morningstar.com/authors/2662/charity-blueChristine Benz  https://www.morningstar.com/authors/30/christine-benzSusan Dziubinski https://www.morningstar.com/authors/12/susan-dziubinskiFollow us on social media.Ivanna Hampton on Twitter: @ivannahampton Christine Benz on Twitter: @Christine_Benz Facebook: https://www.facebook.com/MorningstarInc/    Twitter: https://twitter.com/MorningstarInc    Instagram: https://www.instagram.com/morningstarinc/  LinkedIn: https://www.linkedin.com/company/5161/    

Insulin maker Eli Lilly announced earlier this week that they're capping the out-of-pocket cost of the drug to $35 a month. Plus, Comerica Bank is hosting its Women's Business Symposium in-person for the first time since 2019, and more. Do you have a community story we should tell? Let us know in an email at detroiteveningreport@wdet.org.

Also, Goldman Sachs shares fall 3.8-percent after CEO says “strategic alternatives” are planned for its consumer platforms business. Novavax shares fall 25% after hours. Drugmaker says there is “substantial doubt” about its ability to continue operating this year. Learn more about your ad choices. Visit megaphone.fm/adchoices

英语新闻｜2种新冠药品纳入医保，辉瑞因“报价高”未能进入Pfizer's COVID-19 treatment Paxlovid will not be added to China's updated medical reimbursement list because the company asked for a very high price during the latest round of price negotiations that wrapped up on Sunday, the National Healthcare Security Administration said on Sunday.据国家医疗保障局最新公告，在1月8日结束的最新一轮价格谈判中，Paxlovid因生产企业辉瑞投资有限公司报价高未能成功入选最新的医疗报销清单。However, drugmakers of two other COVID-19 therapies — the homegrown Azvudine and the Qingfei paidu granule, a widely used traditional Chinese medicine to ease COVID-19 symptoms — have successfully struck a deal during the negotiation, said the administration.然而，另外两种缓解新冠肺炎症状的中药，阿兹夫定片、清肺排毒颗粒谈判成功。With the two additions, the administration said that the medical reimbursement list will contain more than 600 types of drugs that have been proven to alleviate fevers, coughing and other COVID-19 symptoms.阿兹夫定片、清肺排毒颗粒经过本次谈判纳入国家医保药品目录后，国家医保药品目录内治疗发热、咳嗽等新冠症状的药品已达600余种。Local healthcare security authorities have also included a number of COVID-19 drugs to their temporary reimbursement lists based on the capacity of local funds.近期各地医保部门结合当地医保基金运行情况，又将一批新冠对症治疗药物临时纳入本地区医保支付范围。Although the highly-anticipated inclusion of Paxlovid was not achieved, the administration said that all COVID-19 drugs listed in the latest version of COVID-19 treatment protocol, including Paxlovid and Merck's Molnupiravir, will be reimbursed through to March 31.尽管大家期待的辉瑞Paxlovid未能成功纳入清单，但有关部门表示，最新版本的新冠肺炎治疗方案中列出的所有药物，包括Paxlovid和默克公司研发的Molnupiravir，患者在2023年3月31日前均可享受到相关的医保报销政策。"We have a rich variety of reimbursable drugs used to treat COVID-19," it said.根据国家医疗保障局最新公告，总体来看，医保报销的新冠病毒感染治疗用药品种丰富。Drugmaker英 [ˈdrʌɡˌmeɪkə] 美 [ˈdrʌɡˌmekər]n. 制药者Alleviate英 [əˈliːvieɪt] 美 [əˈliːvieɪt]v. 减轻、缓和Reimbursement英 [ˌriːɪmˈbɜːsmənt] 美 [ˌriːɪmˈbɜːrsmənt]n. 报销

Some ALS advocates and patients pushed for the drug's release, but the FDA approved Relyvrio without a large-scale human trial. WBZ's Kim Tunnicliffe reports:

Buttigieg: Kavanaugh protesters were exercising First Amendment rights // Drugmaker seeks approval for first nonprescription birth control pill in U.S. // LETTERS  See omnystudio.com/listener for privacy information.

The AP's Jennifer King reports on MED Birth Control Pills FDA Application

Transthyretin amyloid cardiomyopathy, or ATTR-CM, is a progressive and potentially fatal heart disease. It is often overlooked because physicians tend to consider more common causes of heart failure. Black, African American, and Afro-Caribbean communities are at the greatest risk for the genetic condition, but also face greater barriers to accessing care. We spoke to Pfizer Vice President and North America Medical Lead Younos Abdulsattar and Pfizer Chief Medical Officer of Rare Disease Sonal Bhatia, about ATTR-CM; its disproportionate impact on the Black, African American, and Afro-Caribbean communities; and steps Pfizer is taking to work with community organizations to raise awareness and improve care for people with the condition.

A lawsuit brought by the drugmaker Gilead alleges that a counterfeiting ring sold more than 80,000 bottles of fake and possibly unsafe HIV medications to pharmacies over the past two years, worth more than $250 million. Gilead said the bottles had falsified documentation and sometimes contained fake pills, and in some cases made patients sick. For more, we spoke with the Wall Street Journal’s Corrine Ramey, who broke this story Tuesday. Susan Schmidt discusses the potential rise of interest rates in our daily chat about the markets.

A lawsuit brought by the drugmaker Gilead alleges that a counterfeiting ring sold more than 80,000 bottles of fake and possibly unsafe HIV medications to pharmacies over the past two years, worth more than $250 million. Gilead said the bottles had falsified documentation and sometimes contained fake pills, and in some cases made patients sick. For more, we spoke with the Wall Street Journal’s Corrine Ramey, who broke this story Tuesday. Susan Schmidt discusses the potential rise of interest rates in our daily chat about the markets.

NTD Evening News—12/30/2021 1. U.S. Average Daily Covid Cases Over 300,000 2. Twitter Suspends Vax Scientist Permanently 3. Biden Calls Putin, Urges Him To 'de-escalate' 4. Biden Admin Asks SCOTUS To Rule On Remain-in-Mexico 5. Second CNN Producer Leaves Network Amid Allegations Of Sex Crimes Involving Children 6. Times Square Open To Public On New Year's Eve 7. NTD Live Streaming Times Square New Year's Eve Celebrations 8. Drugmaker Teva Found Liable In Opioid Crisis 9. 'Lifetown': Miniature City For Special Needs 10. Confederate Statues To Black History Museum 11. Expert: Maxwell Verdict Not ‘Overall Justice' 12. Coalition Against Drugs Sends Letter To Biden 13. Federal Gov. Approves Calif. Medicaid Changes 14. First Snow Survey And Drought Update 15. College Football Playoff Preview 16. Free Entry Dates To National Parks In 2022 17. Report: Spy Cameras, Blackmail Rampant In China 18. Japan Issues Arrest Warrant For Chinese National 19. China Tech Moguls Lost $80b Of Wealth In 2021 20. Germany Closing 3 Of Its 6 Nuclear Plants 21. What To Do If Your Flight Is Canceled 22. 2021: Illegal Migrant Numbers In EU Hit Record High 23. Metaverse's Dark Side: Assaults & Harassment 24. Big Ben Prepares For New Year's Eve 25. A Look At Space Missions Expected In 2022 26. What Will Cost More In 2022? 27. Newborn Manatee Takes First Swim At Dutch Zoo 28. Cars Covered In Ice After Chilly Sea Journey

Last week, the state of Vermont and four others filed a legal brief seeking to reverse a bankruptcy plan for Purdue Pharma. Vermont Attorney General TJ Donovan says it doesn't hold the company's owners sufficiently accountable.

US drugmaker Merck has announced a deal that could see generic versions of its experimental oral COVID-19 treatment for people infected with the disease widely distributed in poorer countries.The global Medicines Patent Pool which is backed by the United Nations, says it had signed a voluntary licensing agreement with Merck to facilitate affordable worldwide access for its antiviral medicine molnupiravir.Merck and MPP in a statement saying this is the first transparent, public health-driven voluntary license for a COVID-19 medical technology.

US drugmaker Merck has announced a deal that could see generic versions of its experimental oral COVID-19 treatment for people infected with the disease widely distributed in poorer countries.The global Medicines Patent Pool which is backed by the United Nations, says it had signed a voluntary licensing agreement with Merck to facilitate affordable worldwide access for its antiviral medicine molnupiravir.Merck and MPP in a statement saying this is the first transparent, public health-driven voluntary license for a COVID-19 medical technology.

US drugmaker Merck has announced a deal that could see generic versions of its experimental oral COVID-19 treatment for people infected with the disease widely distributed in poorer countries.The global Medicines Patent Pool which is backed by the United Nations, says it had signed a voluntary licensing agreement with Merck to facilitate affordable worldwide access for its antiviral medicine molnupiravir.Merck and MPP in a statement saying this is the first transparent, public health-driven voluntary license for a COVID-19 medical technology.

DrugMaker Merck, announces COVID-19 Pill - Can be taken at home.Subscribe: https://thingsyoushouldknow.supercast.techFacebook: https://www.facebook.com/groups/879254746173653In a potential leap forward in the global fight against the pandemic, drugmaker Merck said Friday that its experimental pill for people sick with COVID-19 reduced hospitalizations and deaths by half.If cleared by regulators, it would be the first pill shown to treat COVID-19, adding a whole new, easy-to-use weapon to an arsenal that already includes the vaccine.The company said it will soon ask health officials in the U.S. and around the world to authorize the pill's use. A decision from the U.S. Food and Drug Administration could come within weeks after that, and the drug, if it gets the OK, could be distributed quickly soon afterward.All other COVID-19 treatments now authorized in the U.S. require an IV or injection. A pill taken at home, by contrast, would ease pressure on hospitals and could also help curb outbreaks in poorer and more remote corners of the world that don't have access to the more expensive infusion therapies.“This would allow us to treat many more people much more quickly and, we trust, much less expensively,” said Dr. William Schaffner, an infectious disease expert at Vanderbilt University who was not involved in the research.Merck and its partner Ridgeback Biotherapeutics said early results showed patients who received the drug, molnupiravir, within five days of COVID-19 symptoms had about half the rate of hospitalization and death as those who received a dummy pill.The study tracked 775 adults with mild-to-moderate COVID-19 who were considered high risk for severe disease because of health problems such as obesity, diabetes or heart disease. The results have not been reviewed by outside experts, the usual procedure for vetting new medical research.Among patients taking molnupiravir, 7.3% were either hospitalized or died at the end of 30 days, compared with 14.1% of those getting the dummy pill. After that time period, there were no deaths among those who received the drug, compared with eight in the placebo group, according to Merck.The results were so strong that an independent group of medical experts monitoring the trial recommended stopping it early.Company executives said they plan to submit the data to the FDA in the coming days.Even with the news of a potentially effective new treatment, experts stressed the importance of vaccines for controlling the pandemic, given that they help prevent transmission and also reduce the severity of illness in those who do get infected.Buzzsprout - Let's get your podcast launched! Start for FREEDisclaimer: This post contains affiliate links. If you make a purchase, I may receive a commission at no extra cost to you.

France's second- largest drug maker, Servier, has been found guilty of manslaughter for deceiving customers about the deadly side effects of its weight loss drug. A Paris court has also pinned part of the blame on the nation's regulators for their refusal to outlaw the pills sooner. But as Paolo Montecillo reports, the penalties on both parties amount to little more than a slap on the wrist. #Servier #BigPhrma #Manslaughter

Drugmaker says vaccine fully prevents severe COVID illness; IMF to upgrade world economic forecast; Canadian Pacific Railway strikes deal to purchase Kansas City Southern for $25 billion

China issues additional quotas for outbound investment. President Xi will attend the Davos Agenda 2021 event next week. The country's housing sales hit a record high last year. A Coronavirus resurgence takes its toll on Chinese airlines. Plus, China’s largest e-cigarette maker is to be listed in the U.S.

Drugmaker says its coronavirus vaccine could be ready for regulators' review by early December. Dow Jones Industrial Average hits intraday record. Nicaragua braces for hit from Hurricane Iota. J.R. Whalen reports. Learn more about your ad choices. Visit megaphone.fm/adchoices

Bayer announces it will spend as much as $4 billion in the acquisition of a gene therapy company. Plus, what toymakers can expect with holiday gift-giving on the horizon. And, gig companies throw more than just money at a ballot initiative in California concerned with how workers are classified in the state.

Bayer announces it will spend as much as $4 billion in the acquisition of a gene therapy company. Plus, what toymakers can expect with holiday gift-giving on the horizon. And, gig companies throw more than just money at a ballot initiative in California concerned with how workers are classified in the state.

Drugmaker says treatment shows promising results in patients with mild-to-moderate Covid-19 cases. U.S. stocks rebound as President Trump signals openness to some stimulus measures. Appeals court says New York prosecutors can obtain Trump tax records. J.R. Whalen reports. Learn more about your ad choices. Visit megaphone.fm/adchoices

Dr. Fauci on not attending today’s briefing with Trump; Dr. Fauci: As a whole, we need to improve testing; Dr. Fauci: I consider myself a realist rather than an alarmist; Dr. Fauci: I would not wait to see if one vaccine is better than another; Dr. Fauci: We should try “as best as we can” to get children back to school; 3 million more infections and 86K deaths since President Trump last held a coronavirus briefing; CDC number of Americans who’ve had COVID-19 could be 6 to 24 times more than the official count; Texas reports several days in a row of over 10,000 new cases; Surgeon General: U.S. needs to lower COVID-19 transmission rate; 54 hospital intensive care units have reached capacity in FL; Drugmaker says Astrazeneca/Oxford vaccine could be ready by Sept.; Meadows on stimulus negotiations: “At our own 20 yard line”; Top WH officials meeting with lawmakers on next economic deal; McConnell supports another round of direct payments to Americans; 1,100 inmates with virus at federal prison in Texas; 500+ women with virus at another Texas facility; While Trump publicly attacks China, the Trump Org has bought more than 8 tons of goods from China; City of Houston lost three employees in one week to virus; Texas border county orders people to stay home as cases surge; To learn more about how CNN protects listener privacy, visit cnn.com/privacy

Drugmaker CEO pours cold water on vaccine hopes.Ruth Bader Ginsburg confirms the recurrence of cancer.Portland protesters say officers are detaining them in unmarked vans.British Airways drops 747 from the fleet.Iconic San Francisco restaurant is going out of business after 86 years.Pressure building on the Iranian regime externally and internally.U.S. postal service slowing down deliveries.Good News: Queen knights 100-year-old Tom Moore.

Executives from drugmaker Insys were the first from the pharmaceutical sector to be handed prison time for their role in America’s opioid epidemic earlier this year. The FT and the PBS series Frontline have investigated why the warning signs around the company were ignored for so long. FT pharmaceutical correspondent Hannah Kuchler tells Marc Filippino what they uncovered.Read the story at ft.com/insys.The PBS Frontline documentary, Opioids, Inc. is available for streaming online at PBS.org beginning Friday June 19, and will premiere on American PBS stations on Tuesday, June 23. For more information visit: https://www.pbs.org/wgbh/frontline/film/opioids-inc/. See acast.com/privacy for privacy and opt-out information.

Brazil to rejects $20m pledged by G7 unless Macron apologises. Opposition MPs agree strategy to block no deal Brexit. Judge orders drugmaker to pay $572 million in opioid lawsuit. You can subscribe to The News with your favourite podcast app or ask your smart speaker to play THE NEWS with Anthony Davis podcast. Follow us on Twitter @TheNews_Podcast The News is an independent production, covering politics, inequality, health and climate - delivering honest, verified, and truthful world news daily. Support the show (https://www.patreon.com/fiveminutenews)

What is the Hyde amendment and why is Joe Biden changing his mind? Drugmaker going bankrupt due to Opiod lawsuits, California giving health care to illegal immigrants, Mexico acting to defray tariffs, Christian florist Barronelle Stutzman still fighting and more!

Rene Thomas Folse, JD, Ph.D. is the host for this edition which reports on the following news stories. Drugmaker's Unorthodox Bid to Protect Patents - Epic Fail, Sutter Health Resolves Inflated Risk Score Claims for $30M, $100K in Cal/OSHA Penalties for Fatal Injury, Two Employers Fined $300K For Finger Amputation, Car Wash Issued $2.36 Million in Wage Theft Citations, 60 Arrested in National 32 Million Pain Pill Bust, Ringleaders of Sham Clinics Plead Guilty, U.S. Physical Therapy Inc., Acquires Third IIP Company, SCIF Suffers $460M Underwriting Loss - No Dividends.

Recorded on Thursday, Jan. 17, this Schaeffer's pod discusses two stocks of China-based companies that recently received bullish analyst attention. We also dig into the rise in shares of PetIQ, recent coverage of Yext, a healthcare stock potentially hurt by the government shutdown, and more.

Recorded on Thursday, Jan. 17, this Schaeffer's pod discusses two stocks of China-based companies that recently received bullish analyst attention. We also dig into the rise in shares of PetIQ, recent coverage of Yext, a healthcare stock potentially hurt by the government shutdown, and more.

(Bloomberg) -- Robert Langreth, a reporter for Bloomberg News, discusses a new IRS probe into the tax-exempt status of a charity funded by pharmaceutical companies, which threatens a pipeline allowing pharmaceutical companies to help patients pay for expensive drugs. He speaks with Greg Stohr and June Grasso on Bloomberg Radio's "Bloomberg Law." Learn more about your ad-choices at https://www.iheartpodcastnetwork.com

(Bloomberg) -- Robert Langreth, a reporter for Bloomberg News, discusses a new IRS probe into the tax-exempt status of a charity funded by pharmaceutical companies, which threatens a pipeline allowing pharmaceutical companies to help patients pay for expensive drugs. He speaks with Greg Stohr and June Grasso on Bloomberg Radio's "Bloomberg Law."

Rene Thomas Folse, JD, Ph.D. is the host for this edition which reports on the following news stories. Drugmaker "Pay for Delay" Deals Decline After Top Court Ruling. Say Goodbye to Some Old Legacy Liens! Nightclub Owner Faces 18 Years for Premium Fraud. Another Contractor Booked for Premium Fraud. Advance-Fee Scam Moves Into Comp Fraud Arena. California has Highest Claim Frequency in Nation. State Attorney Generals Join Health Insurance Merger Probe. Ambulance Fees Reduced in Revised OMFS. U.S. HealthWorks Expands Operations in Bay Area. Emergency Rooms Face Increasing Medication Shortages.

There are opportunities to be had in the biotechnology and pharmaceutical industries, but some investors shy away because of the “Sleep Factor”.  Industry Focus host Kristine Harjes analyzes the drug approval process and why every investor should take a close look at this industry.  She also shares two drugmaker stocks she likes right now, and introduces the term “bleeding event” to the conversation.